PCL-based nanoparticles for doxorubicin-ezetimibe co-delivery: A combination therapy for prostate cancer using a drug repurposing strategy

Mina Yousefnezhad ¹, Soodabeh Davaran ^2,3 * , Mirzaagha Babazadeh ¹, Abolfazl Akbarzadeh ⁴, Hamidreza Pazoki-Toroudi ⁵

Cited by CrossRef: 4

1- Fattahi M, Dehghani M, Paknahad S, Rahiminia S, Zareie D, Hoseini B, Oroomi T, Motedayyen H, Arefnezhad R. Clinical insights into nanomedicine and biosafety: advanced therapeutic approaches for common urological cancers. Front Oncol. 2024;14 [Crossref]

2- Sali A, Duzyer Gebizli S, Goktalay G. Silymarin-loaded electrospun polycaprolactone nanofibers as wound dressing. Journal of Materials Research. 2023;38(8):2251 [Crossref]

3- Patel S, Salaman S, Kapoor D, Yadav R, Sharma S. Latest developments in biomaterial interfaces and drug delivery: challenges, innovations, and future outlook. 2024; [Crossref]

4- Alizadehasl A, Alavi M, Boudagh S, Alavi M, Mohebi S, Aliabadi L, Akbarian M, Ahmadi P, Mannarino M, Sahebkar A. Lipid-lowering drugs and cancer: an updated perspective. Pharmacol Rep. 2024;76(1):1 [Crossref]

Submit Your Paper Instructions for Authors Aims and Scope Editorial Board Editorial Policies Publication Ethics Policies Editorial Board Policy Abstracting and Indexing Archive

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences.
Acceptance rate: 24%
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded, Google Scholar; SJR ; Essential Science Indicators; Publons; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO; Ulrich
Member of COPE
Follower of ICMJE
Permission: Creative Commons